| Net profit of Astrazeneca Pharma India declined 22.95% to Rs 44.88 crore in the quarter ended March 2026 as against Rs 58.25 crore during the previous quarter ended March 2025. Sales rose 20.42% to Rs 578.61 crore in the quarter ended March 2026 as against Rs 480.48 crore during the previous quarter ended March 2025.
For the full year,net profit rose 62.02% to Rs 187.52 crore in the year ended March 2026 as against Rs 115.74 crore during the previous year ended March 2025. Sales rose 32.59% to Rs 2275.58 crore in the year ended March 2026 as against Rs 1716.29 crore during the previous year ended March 2025.
| Particulars | Quarter Ended | Year Ended | | Mar. 2026 | Mar. 2025 | % Var. | Mar. 2026 | Mar. 2025 | % Var. |
| Sales | 578.61 | 480.48 | 20 | 2275.58 | 1716.29 | 33 |
| OPM % | 10.53 | 17.98 | - | 11.51 | 14.80 | - |
| PBDT | 64.82 | 101.84 | -36 | 286.03 | 293.14 | -2 |
| PBT | 59.22 | 84.15 | -30 | 257.45 | 253.15 | 2 |
| NP | 44.88 | 58.25 | -23 | 187.52 | 115.74 | 62 |
|